Skip to main content
OpenTrials
Completed

NCT Number: NCT06309459

Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma

Triple-negative breast carcinoma is characterized by the absence of estrogen receptors, progesterone receptors, and HER2/neu receptors. Carbonic anhydrase IX (CA IX) is a tumor-associated cell surface glycoprotein that is involved in adaptation to hypoxia-induced acidosis and plays a role in cancer progression. This study aimed to investigate CA IX expression in TNBC and its relationship with treatment effect.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Triple Negative Breast Cancer Breast Diseases Breast Neoplasms Carbonic Anhydrase IX Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases Triple Negative Breast Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Kahramanmaraş Sütçü İmam University

Kahramanmaraş, 46000, Turkey (Türkiye)

About this study

Tru-cut biopsy materials, sent to our hospital pathology laboratory between August 2018 and May 2023, will be examined. Invasive carcinoma cases will be evaluated according to estrogen, progesterone, and HER 2 receptor levels. Triple-negative tumor cases were isolated and those cases who underwent breast resection in our hospital after receiving neoadjuvant chemotherapy (Adriamycin, cyclophosphamide, and then paclitaxel for 4 cycles) were included in the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Older than 18 years
  • Triple-negative mastectomy cases
  • Patients whose data can be available
  • Patients who were operated in our hospital

Exclusion criteria

  • Younger than 18 years
  • Not triple negative mastectomy cases
  • Patients with missing data
  • Patients who were operated in another hospital

Treatment and study plan

Carbonic anhydrase staining levels

Diagnostic Test

CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as Low staining if they constituted <10% of the total and high staining if they constituted ≥ 10% (15).

Primary outcomes

  1. Poor prognostic factors in patients with TNBC

    Time frame: 2018-2023

    Higher staining CA IX levels (≥ 10%) in TNBC patients' pathological specimens is a poor prognostic factor

  2. The treatment success with inhibiting the CA IX enzyme levels' effectiveness

    Time frame: 2018-2023

    Treatment success in TNBC patients by evaluating changes in CA IX staining levels

Sponsors and collaborators

Lead sponsor

Kahramanmaras Sutcu Imam University

Other

Registry information

Official study title

Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma: Relationship With Prognostic Factors and Response to Neoadjuvant Chemotherapy

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Mar 13, 2024
Registry last updated
Mar 13, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.